{"transactions":[{"id":4617917,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-15T20:15:14.000Z","date":"2026-09-14","kind":"sale","planned":true,"acquired":false,"shares":6602,"price":14.12,"value":93220.24,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.59 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, L.P. (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":132650,"source":{"system":"sec-edgar","filing":"0001030575-26-000014","document":"form4-09152026_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000103057526000014/form4-09152026_040901.xml","form_type":"4"}},{"id":4617916,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-15T20:15:14.000Z","date":"2026-09-14","kind":"sale","planned":true,"acquired":false,"shares":31888,"price":14.12,"value":450258.56,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.59 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas XI\"). Atlas Venture Associates XI, L.P. (\"AVA XI LP\") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":640610,"source":{"system":"sec-edgar","filing":"0001030575-26-000014","document":"form4-09152026_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000103057526000014/form4-09152026_040901.xml","form_type":"4"}},{"id":4617915,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-15T20:15:14.000Z","date":"2026-09-11","kind":"sale","planned":true,"acquired":false,"shares":1750,"price":13.99,"value":24482.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, L.P. (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":139252,"source":{"system":"sec-edgar","filing":"0001030575-26-000014","document":"form4-09152026_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000103057526000014/form4-09152026_040901.xml","form_type":"4"}},{"id":4617914,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-15T20:15:14.000Z","date":"2026-09-11","kind":"sale","planned":true,"acquired":false,"shares":8450,"price":13.99,"value":118215.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas XI\"). Atlas Venture Associates XI, L.P. (\"AVA XI LP\") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":672498,"source":{"system":"sec-edgar","filing":"0001030575-26-000014","document":"form4-09152026_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000103057526000014/form4-09152026_040901.xml","form_type":"4"}},{"id":4616817,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":29811,"kind":"person","name":"Dolan Oliver","position":1,"cik":"0002053835","reported_name":"Dolan Oliver","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Common Stock","published_at":"2026-09-14T20:05:25.000Z","date":"2026-09-11","kind":"sale","planned":true,"acquired":false,"shares":5,"price":13.716,"value":68.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions at prices ranging from $13.51 to $13.85, inclusive. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 16,241 shares of common stock issuable upon settlement of restricted stock units (RSUs) that remain unvested, consisting of 10,741 shares that will vest on December 15, 2026, 2,750 shares that will vest on July 15, 2027, and 2,750 shares that will vest on July 15, 2028, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date."}],"balance_after":16241,"source":{"system":"sec-edgar","filing":"0001193125-26-390556","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2053835/000119312526390556/ownership.xml","form_type":"4"}},{"id":4614521,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":29811,"kind":"person","name":"Dolan Oliver","position":1,"cik":"0002053835","reported_name":"Dolan Oliver","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Common Stock","published_at":"2026-09-10T20:05:03.000Z","date":"2026-09-09","kind":"sale","planned":true,"acquired":false,"shares":6,"price":13.6033,"value":81.6198,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions at prices ranging from $13.52 to $13.76, inclusive. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 16,241 shares of common stock issuable upon settlement of restricted stock units (RSUs) that remain unvested, consisting of 10,741 shares that will vest on December 15, 2026, 2,750 shares that will vest on July 15, 2027, and 2,750 shares that will vest on July 15, 2028, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date."}],"balance_after":16246,"source":{"system":"sec-edgar","filing":"0001193125-26-387852","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2053835/000119312526387852/ownership.xml","form_type":"4"}},{"id":4614520,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":29811,"kind":"person","name":"Dolan Oliver","position":1,"cik":"0002053835","reported_name":"Dolan Oliver","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Common Stock","published_at":"2026-09-10T20:05:03.000Z","date":"2026-09-08","kind":"sale","planned":true,"acquired":false,"shares":7347,"price":13.5138,"value":99285.8886,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions at prices ranging from $13.50 to $13.595, inclusive. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 16,241 shares of common stock issuable upon settlement of restricted stock units (RSUs) that remain unvested, consisting of 10,741 shares that will vest on December 15, 2026, 2,750 shares that will vest on July 15, 2027, and 2,750 shares that will vest on July 15, 2028, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date."}],"balance_after":16252,"source":{"system":"sec-edgar","filing":"0001193125-26-387852","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2053835/000119312526387852/ownership.xml","form_type":"4"}},{"id":673228,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-28T16:30:08.000Z","date":"2026-08-26","kind":"sale","planned":true,"acquired":false,"shares":51,"price":13.96,"value":711.96,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.955 to $13.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, L.P. (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":141002,"source":{"system":"sec-edgar","filing":"0001030575-26-000012","document":"form4-08282026_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000012/form4-08282026_040801.xml","form_type":"4"}},{"id":673227,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-28T16:30:08.000Z","date":"2026-08-26","kind":"sale","planned":true,"acquired":false,"shares":249,"price":13.96,"value":3476.04,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.955 to $13.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas XI\"). Atlas Venture Associates XI, L.P. (\"AVA XI LP\") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":680948,"source":{"system":"sec-edgar","filing":"0001030575-26-000012","document":"form4-08282026_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000012/form4-08282026_040801.xml","form_type":"4"}},{"id":679218,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-21T20:20:01.000Z","date":"2026-08-19","kind":"sale","planned":true,"acquired":false,"shares":4884,"price":14,"value":68376.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, L.P. (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":141053,"source":{"system":"sec-edgar","filing":"0001030575-26-000010","document":"form4-08212026_080856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000010/form4-08212026_080856.xml","form_type":"4"}},{"id":679217,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-21T20:20:01.000Z","date":"2026-08-19","kind":"sale","planned":true,"acquired":false,"shares":23584,"price":14,"value":330176.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas XI\"). Atlas Venture Associates XI, L.P. (\"AVA XI LP\") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":681197,"source":{"system":"sec-edgar","filing":"0001030575-26-000010","document":"form4-08212026_080856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000010/form4-08212026_080856.xml","form_type":"4"}},{"id":688298,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-13T21:04:38.000Z","date":"2026-08-11","kind":"sale","planned":true,"acquired":false,"shares":368,"price":13.96,"value":5137.28,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, L.P. (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":145937,"source":{"system":"sec-edgar","filing":"0001030575-26-000008","document":"form4-08132026_090834.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000008/form4-08132026_090834.xml","form_type":"4"}},{"id":688297,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-13T21:04:38.000Z","date":"2026-08-11","kind":"sale","planned":true,"acquired":false,"shares":1775,"price":13.96,"value":24779.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas XI\"). Atlas Venture Associates XI, L.P. (\"AVA XI LP\") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":704781,"source":{"system":"sec-edgar","filing":"0001030575-26-000008","document":"form4-08132026_090834.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000008/form4-08132026_090834.xml","form_type":"4"}},{"id":687681,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.001 par value per share","published_at":"2026-08-13T13:54:20.000Z","date":"2026-08-10","kind":"purchase","planned":false,"acquired":true,"shares":1462,"price":13.1869,"value":19279.2478,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.11 to $13.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":1544980,"source":{"system":"sec-edgar","filing":"0000902664-26-003434","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000090266426003434/ownership.xml","form_type":"4"}},{"id":687680,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.001 par value per share","published_at":"2026-08-13T13:54:20.000Z","date":"2026-08-06","kind":"purchase","planned":false,"acquired":true,"shares":5222,"price":11.3998,"value":59529.7556,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.39 to $11.40 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":1543518,"source":{"system":"sec-edgar","filing":"0000902664-26-003434","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000090266426003434/ownership.xml","form_type":"4"}},{"id":695229,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":26137,"kind":"person","name":"Aiyar Ram","position":1,"cik":"0001997920","reported_name":"Aiyar Ram","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-08-05T20:05:09.000Z","date":"2026-08-04","kind":"sale","planned":false,"acquired":false,"shares":5802,"price":10.844,"value":62916.888,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the mandatory sale of shares of common stock solely to satisfy tax withholding obligations incurred upon vesting and settlement of a restricted stock unit (RSU) granted under the Issuer's 2023 Stock Option and Incentive Plan (the 2023 Plan)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions at prices ranging from $10.57 to $11.055, inclusive. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 20,000 shares of common stock issuable upon settlement of a RSU granted under the 2023 Plan that will vest on February 1, 2027 subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through such date."}],"balance_after":69046,"source":{"system":"sec-edgar","filing":"0001193125-26-335041","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312526335041/ownership.xml","form_type":"4"}},{"id":706371,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":29672,"kind":"person","name":"Vincent Loic A","position":1,"cik":"0002063400","reported_name":"Vincent Loic A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-07-17T11:14:03.000Z","date":"2026-07-15","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon settlement of a restricted stock unit (RSU) granted under the Issuer's 2023 Stock Option and Incentive Plan (the 2023 Plan) that will vest as follows: 50% on July 15, 2027 and 50% on July 15, 2028, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 18,358 shares of common stock issuable upon settlement of restricted stock units (RSUs) that remain unvested, consisting of 10,858 shares that will vest on December 15, 2026, 3,750 shares that will vest on July 15, 2027, and 3,750 shares that will vest on July 15, 2028, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date."}],"balance_after":25797,"source":{"system":"sec-edgar","filing":"0001193125-26-306743","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312526306743/ownership.xml","form_type":"4"}},{"id":707126,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":29811,"kind":"person","name":"Dolan Oliver","position":1,"cik":"0002053835","reported_name":"Dolan Oliver","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Common Stock","published_at":"2026-07-17T11:11:03.000Z","date":"2026-07-15","kind":"grant","planned":false,"acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon settlement of a restricted stock unit (RSU) granted under the Issuer's 2023 Stock Option and Incentive Plan (the 2023 Plan) that will vest as follows: 50% on July 15, 2027 and 50% on July 15, 2028, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 16,241 shares of common stock issuable upon settlement of restricted stock units (RSUs) that remain unvested, consisting of 10,741 shares that will vest on December 15, 2026, 2,750 shares that will vest on July 15, 2027, and 2,750 shares that will vest on July 15, 2028, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date."}],"balance_after":23599,"source":{"system":"sec-edgar","filing":"0001193125-26-306742","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2053835/000119312526306742/ownership.xml","form_type":"4"}},{"id":707114,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":29801,"kind":"person","name":"Cerio Jeffrey","position":1,"cik":"0002033618","reported_name":"Cerio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-07-17T11:08:03.000Z","date":"2026-07-15","kind":"grant","planned":false,"acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon settlement of a restricted stock unit (RSU) granted under the Issuer's 2023 Stock Option and Incentive Plan (the 2023 Plan) that will vest as follows: 50% on July 15, 2027 and 50% on July 15, 2028, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 27,451 shares of common stock issuable upon settlement of restricted stock units (RSUs) that remain unvested, consisting of 20,951 shares that will vest on December 15, 2026, 3,250 shares that will vest on July 15, 2027, and 3,250 shares that will vest on July 15, 2028, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date."}],"balance_after":41793,"source":{"system":"sec-edgar","filing":"0001193125-26-306739","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2033618/000119312526306739/ownership.xml","form_type":"4"}},{"id":706370,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":29671,"kind":"person","name":"Chappell Todd","position":1,"cik":"0001997992","reported_name":"Chappell Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-07-17T11:05:03.000Z","date":"2026-07-15","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon settlement of a restricted stock unit (RSU) granted under the Issuer's 2023 Stock Option and Incentive Plan (the 2023 Plan) that will vest as follows: 50% on July 15, 2027 and 50% on July 15, 2028, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 17,566 shares of common stock issuable upon settlement of restricted stock units (RSUs) that remain unvested, consisting of 10,066 shares that will vest on December 15, 2026, 3,750 shares that will vest on July 15, 2027, and 3,750 shares that will vest on July 15, 2028, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date."}],"balance_after":24464,"source":{"system":"sec-edgar","filing":"0001193125-26-306733","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312526306733/ownership.xml","form_type":"4"}},{"id":713920,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-07T22:04:30.000Z","date":"2026-07-06","kind":"sale","planned":true,"acquired":false,"shares":8506,"price":13.96,"value":118743.76,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.05 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, L.P. (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":146305,"source":{"system":"sec-edgar","filing":"0001030575-26-000006","document":"form4-07072026_100726.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000006/form4-07072026_100726.xml","form_type":"4"}},{"id":713919,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-07T22:04:30.000Z","date":"2026-07-06","kind":"sale","planned":true,"acquired":false,"shares":817,"price":13.96,"value":11405.32,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.05 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas XI\"). Atlas Venture Associates XI, L.P. (\"AVA XI LP\") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":706556,"source":{"system":"sec-edgar","filing":"0001030575-26-000006","document":"form4-07072026_100726.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000006/form4-07072026_100726.xml","form_type":"4"}},{"id":713918,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-07T22:04:30.000Z","date":"2026-07-02","kind":"sale","planned":true,"acquired":false,"shares":14745,"price":14.03,"value":206872.35,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.16 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2) and (5)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, L.P. (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":154811,"source":{"system":"sec-edgar","filing":"0001030575-26-000006","document":"form4-07072026_100726.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000006/form4-07072026_100726.xml","form_type":"4"}},{"id":713917,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-07T22:04:30.000Z","date":"2026-07-02","kind":"sale","planned":true,"acquired":false,"shares":85955,"price":14.03,"value":1205948.65,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.16 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2) and (5)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas XI\"). Atlas Venture Associates XI, L.P. (\"AVA XI LP\") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":707373,"source":{"system":"sec-edgar","filing":"0001030575-26-000006","document":"form4-07072026_100726.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000006/form4-07072026_100726.xml","form_type":"4"}},{"id":728079,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-25T00:09:15.000Z","date":"2026-06-24","kind":"sale","planned":true,"acquired":false,"shares":114,"price":14.98,"value":1707.72,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.97 to $15.10 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, L.P. (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":169556,"source":{"system":"sec-edgar","filing":"0001030575-26-000004","document":"form4-06252026_120611.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000004/form4-06252026_120611.xml","form_type":"4"}},{"id":728078,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-25T00:09:15.000Z","date":"2026-06-24","kind":"sale","planned":true,"acquired":false,"shares":6979,"price":14.6,"value":101893.4,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.88 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, L.P. (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":169670,"source":{"system":"sec-edgar","filing":"0001030575-26-000004","document":"form4-06252026_120611.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000004/form4-06252026_120611.xml","form_type":"4"}},{"id":728077,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-25T00:09:15.000Z","date":"2026-06-24","kind":"sale","planned":true,"acquired":false,"shares":666,"price":14.98,"value":9976.68,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.97 to $15.10 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas XI\"). Atlas Venture Associates XI, L.P. (\"AVA XI LP\") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":793328,"source":{"system":"sec-edgar","filing":"0001030575-26-000004","document":"form4-06252026_120611.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000004/form4-06252026_120611.xml","form_type":"4"}},{"id":728076,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-25T00:09:15.000Z","date":"2026-06-24","kind":"sale","planned":true,"acquired":false,"shares":40679,"price":14.6,"value":593913.4,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.88 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas XI\"). Atlas Venture Associates XI, L.P. (\"AVA XI LP\") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":793994,"source":{"system":"sec-edgar","filing":"0001030575-26-000004","document":"form4-06252026_120611.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000004/form4-06252026_120611.xml","form_type":"4"}},{"id":728075,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-25T00:09:15.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":17426,"price":14.25,"value":248320.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (4), (5) and (6)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, L.P. (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":176649,"source":{"system":"sec-edgar","filing":"0001030575-26-000004","document":"form4-06252026_120611.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000004/form4-06252026_120611.xml","form_type":"4"}},{"id":728074,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-25T00:09:15.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":101579,"price":14.25,"value":1447500.75,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (4), (5) and (6)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas XI\"). Atlas Venture Associates XI, L.P. (\"AVA XI LP\") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":834673,"source":{"system":"sec-edgar","filing":"0001030575-26-000004","document":"form4-06252026_120611.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000004/form4-06252026_120611.xml","form_type":"4"}},{"id":728073,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-25T00:09:15.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":580,"price":13.95,"value":8091.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, L.P. (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":194075,"source":{"system":"sec-edgar","filing":"0001030575-26-000004","document":"form4-06252026_120611.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000004/form4-06252026_120611.xml","form_type":"4"}},{"id":728072,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-25T00:09:15.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":3382,"price":13.95,"value":47178.9,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas XI\"). Atlas Venture Associates XI, L.P. (\"AVA XI LP\") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":936252,"source":{"system":"sec-edgar","filing":"0001030575-26-000004","document":"form4-06252026_120611.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000004/form4-06252026_120611.xml","form_type":"4"}},{"id":733269,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":29671,"kind":"person","name":"Chappell Todd","position":1,"cik":"0001997992","reported_name":"Chappell Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-06-17T20:14:03.000Z","date":"2026-06-16","kind":"sale","planned":false,"acquired":false,"shares":3168,"price":10.83,"value":34309.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the mandatory sale of shares of common stock solely to satisfy tax withholding obligations incurred upon vesting and settlement of a restricted stock unit (RSU) granted under the Issuer's 2023 Stock Option and Incentive Plan (the 2023 Plan)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions at prices ranging from $10.58 to $11.35, inclusive. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 10,066 shares of common stock issuable upon settlement of a RSU granted under the 2023 Plan that will vest on December 15, 2026 subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through such date."}],"balance_after":16964,"source":{"system":"sec-edgar","filing":"0001193125-26-274171","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312526274171/ownership.xml","form_type":"4"}},{"id":733268,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":29672,"kind":"person","name":"Vincent Loic A","position":1,"cik":"0002063400","reported_name":"Vincent Loic A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-06-17T20:11:04.000Z","date":"2026-06-16","kind":"sale","planned":false,"acquired":false,"shares":3418,"price":10.83,"value":37016.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the mandatory sale of shares of common stock solely to satisfy tax withholding obligations incurred upon vesting and settlement of a restricted stock unit (RSU) granted under the Issuer's 2023 Stock Option and Incentive Plan (the 2023 Plan)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions at prices ranging from $10.58 to $11.35, inclusive. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 10,858 shares of common stock issuable upon settlement of a RSU granted under the 2023 Plan that will vest on December 15, 2026 subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through such date."}],"balance_after":18297,"source":{"system":"sec-edgar","filing":"0001193125-26-274156","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312526274156/ownership.xml","form_type":"4"}},{"id":734540,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":29801,"kind":"person","name":"Cerio Jeffrey","position":1,"cik":"0002033618","reported_name":"Cerio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-06-17T20:08:03.000Z","date":"2026-06-16","kind":"sale","planned":false,"acquired":false,"shares":6609,"price":10.83,"value":71575.47,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the mandatory sale of shares of common stock solely to satisfy tax withholding obligations incurred upon vesting and settlement of a restricted stock unit (RSU) granted under the Issuer's 2023 Stock Option and Incentive Plan (the 2023 Plan)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions at prices ranging from $10.58 to $11.35, inclusive. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 20,951 shares of common stock issuable upon settlement of a RSU granted under the 2023 Plan that will vest on December 15, 2026 subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through such date."}],"balance_after":35293,"source":{"system":"sec-edgar","filing":"0001193125-26-274143","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2033618/000119312526274143/ownership.xml","form_type":"4"}},{"id":734574,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":29811,"kind":"person","name":"Dolan Oliver","position":1,"cik":"0002053835","reported_name":"Dolan Oliver","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Common Stock","published_at":"2026-06-17T20:05:26.000Z","date":"2026-06-16","kind":"sale","planned":false,"acquired":false,"shares":3383,"price":10.83,"value":36637.89,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the mandatory sale of shares of common stock solely to satisfy tax withholding obligations incurred upon vesting and settlement of a restricted stock unit (RSU) granted under the Issuer's 2023 Stock Option and Incentive Plan (the 2023 Plan)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions at prices ranging from $10.58 to $11.35, inclusive. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 10,741 shares of common stock issuable upon settlement of a RSU granted under the 2023 Plan that will vest on December 15, 2026 subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through such date."}],"balance_after":18099,"source":{"system":"sec-edgar","filing":"0001193125-26-274136","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2053835/000119312526274136/ownership.xml","form_type":"4"}},{"id":741209,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T22:10:20.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":14677,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date."}],"balance_after":14677,"derivative":{"exercise_price":10.59,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":14677},"source":{"system":"sec-edgar","filing":"0001193125-26-268018","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526268018/ownership.xml","form_type":"4"}},{"id":741973,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":39332,"kind":"person","name":"Meyers Rachel","position":1,"cik":"0002001472","reported_name":"Meyers Rachel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T22:07:03.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":14677,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date."}],"balance_after":14677,"derivative":{"exercise_price":10.59,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":14677},"source":{"system":"sec-edgar","filing":"0001193125-26-268012","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2001472/000119312526268012/ownership.xml","form_type":"4"}},{"id":741484,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":39214,"kind":"person","name":"Bermingham Nessan","position":1,"cik":"0001377759","reported_name":"Bermingham Nessan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T22:04:03.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":14677,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date."}],"balance_after":14677,"derivative":{"exercise_price":10.59,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":14677},"source":{"system":"sec-edgar","filing":"0001193125-26-268006","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377759/000119312526268006/ownership.xml","form_type":"4"}},{"id":741160,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":39150,"kind":"person","name":"Knobil Katharine","position":1,"cik":"0001768011","reported_name":"Knobil Katharine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T22:01:03.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":14677,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date."}],"balance_after":14677,"derivative":{"exercise_price":10.59,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":14677},"source":{"system":"sec-edgar","filing":"0001193125-26-268001","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312526268001/ownership.xml","form_type":"4"}},{"id":742134,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T21:58:03.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":14677,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date."}],"balance_after":14677,"derivative":{"exercise_price":10.59,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":14677},"source":{"system":"sec-edgar","filing":"0001193125-26-267996","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000119312526267996/ownership.xml","form_type":"4"}},{"id":741248,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":39174,"kind":"person","name":"PEARSON TIMOTHY R","position":1,"cik":"0001528617","reported_name":"PEARSON TIMOTHY R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T21:55:03.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":14677,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date."}],"balance_after":14677,"derivative":{"exercise_price":10.59,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":14677},"source":{"system":"sec-edgar","filing":"0001193125-26-267993","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1528617/000119312526267993/ownership.xml","form_type":"4"}},{"id":753992,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":26137,"kind":"person","name":"Aiyar Ram","position":1,"cik":"0001997920","reported_name":"Aiyar Ram","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-06-02T11:00:03.000Z","date":"2026-05-29","kind":"sale","planned":false,"acquired":false,"shares":15152,"price":12.98,"value":196672.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the sale of shares of common stock solely to satisfy tax withholding obligations incurred upon vesting and settlement of a performance stock unit."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions at prices ranging from $12.62 to $13.245, inclusive. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 40,000 shares of common stock issuable upon settlement of a restricted stock unit granted under the 2023 Plan as reported on Form 4 dated February 3, 2026."}],"balance_after":74848,"source":{"system":"sec-edgar","filing":"0001193125-26-252460","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312526252460/ownership.xml","form_type":"4"}},{"id":757646,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-01T21:35:05.000Z","date":"2026-05-28","kind":"sale","planned":true,"acquired":false,"shares":419,"price":13.95,"value":5845.05,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, L.P. (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":194655,"source":{"system":"sec-edgar","filing":"0001030575-26-000002","document":"form4-06012026_050601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000002/form4-06012026_050601.xml","form_type":"4"}},{"id":757645,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-01T21:35:05.000Z","date":"2026-05-28","kind":"sale","planned":true,"acquired":false,"shares":2441,"price":13.95,"value":34051.95,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas XI\"). Atlas Venture Associates XI, L.P. (\"AVA XI LP\") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":939634,"source":{"system":"sec-edgar","filing":"0001030575-26-000002","document":"form4-06012026_050601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000103057526000002/form4-06012026_050601.xml","form_type":"4"}},{"id":759810,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":26137,"kind":"person","name":"Aiyar Ram","position":1,"cik":"0001997920","reported_name":"Aiyar Ram","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-05-28T21:07:15.000Z","date":"2026-05-26","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":12.33,"value":616500.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares of common stock issued upon settlement and vesting of a performance stock unit (PSU) granted under the Issuer's 2023 Stock Option and Incentive Plan (the 2023 Plan) that vested and settled upon achievement of the performance condition on May 26, 2026."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issued upon settlement and vesting of a performance stock unit (PSU) granted under the Issuer's 2023 Stock Option and Incentive Plan (the 2023 Plan) that vested and settled upon achievement of the performance condition on May 26, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 40,000 shares of common stock issuable upon settlement of a restricted stock unit granted under the 2023 Plan as reported on Form 4 dated February 3, 2026."}],"balance_after":90000,"source":{"system":"sec-edgar","filing":"0001193125-26-245491","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312526245491/ownership.xml","form_type":"4"}},{"id":818821,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.001 par value per share","published_at":"2026-04-02T16:00:58.000Z","date":"2026-03-31","kind":"purchase","planned":false,"acquired":true,"shares":520,"price":10.6,"value":5512.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":1538296,"source":{"system":"sec-edgar","filing":"0000902664-26-001845","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000090266426001845/ownership.xml","form_type":"4"}},{"id":845778,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":23294,"kind":"person","name":"SANDELL SCOTT D","position":1,"cik":"0001237289","reported_name":"SANDELL SCOTT D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2026-03-13T00:15:15.000Z","date":"2026-03-10","kind":"purchase","planned":false,"acquired":true,"shares":242945,"price":11.109,"value":2698876.005,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":242945,"derivative":{"exercise_price":0.001,"underlying":"Common Stock","underlying_shares":242945},"source":{"system":"sec-edgar","filing":"0001193125-26-104720","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1237289/000119312526104720/ownership.xml","form_type":"4"}},{"id":845777,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":23294,"kind":"person","name":"SANDELL SCOTT D","position":1,"cik":"0001237289","reported_name":"SANDELL SCOTT D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-13T00:15:15.000Z","date":"2026-03-10","kind":"purchase","planned":false,"acquired":true,"shares":207100,"price":11.11,"value":2300881.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":1297893,"source":{"system":"sec-edgar","filing":"0001193125-26-104720","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237289/000119312526104720/ownership.xml","form_type":"4"}},{"id":845409,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":38171,"kind":"person","name":"Chang Carmen","position":1,"cik":"0001746342","reported_name":"Chang Carmen","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2026-03-13T00:15:12.000Z","date":"2026-03-10","kind":"purchase","planned":false,"acquired":true,"shares":242945,"price":11.109,"value":2698876.005,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":242945,"derivative":{"exercise_price":0.001,"underlying":"Common Stock","underlying_shares":242945},"source":{"system":"sec-edgar","filing":"0001193125-26-104717","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312526104717/ownership.xml","form_type":"4"}},{"id":845408,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":38171,"kind":"person","name":"Chang Carmen","position":1,"cik":"0001746342","reported_name":"Chang Carmen","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-13T00:15:12.000Z","date":"2026-03-10","kind":"purchase","planned":false,"acquired":true,"shares":207100,"price":11.11,"value":2300881.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":1297893,"source":{"system":"sec-edgar","filing":"0001193125-26-104717","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312526104717/ownership.xml","form_type":"4"}},{"id":845506,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2026-03-13T00:15:10.000Z","date":"2026-03-10","kind":"grant","planned":false,"acquired":true,"shares":242945,"price":11.109,"value":2698876.005,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":242945,"derivative":{"exercise_price":0.001,"underlying":"Common Stock","underlying_shares":242945},"source":{"system":"sec-edgar","filing":"0001193125-26-104718","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526104718/ownership.xml","form_type":"4"}},{"id":845505,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-13T00:15:10.000Z","date":"2026-03-10","kind":"grant","planned":false,"acquired":true,"shares":207100,"price":11.11,"value":2300881.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":1297893,"source":{"system":"sec-edgar","filing":"0001193125-26-104718","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526104718/ownership.xml","form_type":"4"}},{"id":845743,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2026-03-13T00:15:07.000Z","date":"2026-03-10","kind":"purchase","planned":false,"acquired":true,"shares":242945,"price":11.109,"value":2698876.005,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":242945,"derivative":{"exercise_price":0.001,"underlying":"Common Stock","underlying_shares":242945},"source":{"system":"sec-edgar","filing":"0001193125-26-104715","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312526104715/ownership.xml","form_type":"4"}},{"id":845742,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-13T00:15:07.000Z","date":"2026-03-10","kind":"purchase","planned":false,"acquired":true,"shares":207100,"price":11.11,"value":2300881.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":1297893,"source":{"system":"sec-edgar","filing":"0001193125-26-104715","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312526104715/ownership.xml","form_type":"4"}},{"id":845490,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":23295,"kind":"person","name":"Makhzoumi Mohamad","position":1,"cik":"0001630226","reported_name":"Makhzoumi Mohamad","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2026-03-13T00:15:06.000Z","date":"2026-03-10","kind":"purchase","planned":false,"acquired":true,"shares":242945,"price":11.109,"value":2698876.005,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":242945,"derivative":{"exercise_price":0.001,"underlying":"Common Stock","underlying_shares":242945},"source":{"system":"sec-edgar","filing":"0001193125-26-104713","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1630226/000119312526104713/ownership.xml","form_type":"4"}},{"id":845489,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":23295,"kind":"person","name":"Makhzoumi Mohamad","position":1,"cik":"0001630226","reported_name":"Makhzoumi Mohamad","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-13T00:15:06.000Z","date":"2026-03-10","kind":"purchase","planned":false,"acquired":true,"shares":207100,"price":11.11,"value":2300881.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":1297893,"source":{"system":"sec-edgar","filing":"0001193125-26-104713","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1630226/000119312526104713/ownership.xml","form_type":"4"}},{"id":845613,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":23293,"kind":"person","name":"Florence Anthony A. Jr.","position":1,"cik":"0001559827","reported_name":"Florence Anthony A. Jr.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2026-03-13T00:15:03.000Z","date":"2026-03-10","kind":"purchase","planned":false,"acquired":true,"shares":242945,"price":11.109,"value":2698876.005,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":242945,"derivative":{"exercise_price":0.001,"underlying":"Common Stock","underlying_shares":242945},"source":{"system":"sec-edgar","filing":"0001193125-26-104712","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1559827/000119312526104712/ownership.xml","form_type":"4"}},{"id":845612,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":23293,"kind":"person","name":"Florence Anthony A. Jr.","position":1,"cik":"0001559827","reported_name":"Florence Anthony A. Jr.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-13T00:15:03.000Z","date":"2026-03-10","kind":"purchase","planned":false,"acquired":true,"shares":207100,"price":11.11,"value":2300881.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":1297893,"source":{"system":"sec-edgar","filing":"0001193125-26-104712","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1559827/000119312526104712/ownership.xml","form_type":"4"}},{"id":846358,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2026-03-12T20:15:16.000Z","date":"2026-03-10","kind":"purchase","planned":false,"acquired":true,"shares":242945,"price":11.109,"value":2698876.005,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":242945,"derivative":{"exercise_price":0.001,"underlying":"Common Stock","underlying_shares":242945},"source":{"system":"sec-edgar","filing":"0001193125-26-104721","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312526104721/ownership.xml","form_type":"4"}},{"id":846357,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-12T20:15:16.000Z","date":"2026-03-10","kind":"purchase","planned":false,"acquired":true,"shares":207100,"price":11.11,"value":2300881.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":1297893,"source":{"system":"sec-edgar","filing":"0001193125-26-104721","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312526104721/ownership.xml","form_type":"4"}},{"id":846293,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":61257,"kind":"organization","name":"New Enterprise Associates 17, L.P.","position":1,"cik":"0001768564","reported_name":"New Enterprise Associates 17, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61258,"kind":"organization","name":"NEA Partners 17, L.P.","position":2,"cik":"0001796820","reported_name":"NEA Partners 17, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61259,"kind":"organization","name":"NEA 17 GP, LLC","position":3,"cik":"0001796821","reported_name":"NEA 17 GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2026-03-12T20:15:13.000Z","date":"2026-03-10","kind":"purchase","planned":false,"acquired":true,"shares":242945,"price":11.109,"value":2698876.005,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by New Enterprise Associates 17, L.P. (\"NEA 17\") and are indirectly held by NEA Partners 17, L.P. (\"NEA Partners 17\"), the sole general partner of NEA 17, NEA 17 GP, LLC (\"NEA 17 GP\"), the sole general partner of NEA Partners 17, and the individual managers of NEA 17 GP (NEA Partners 17, NEA 17 GP and the individual managers of NEA 17 GP (collectively, the \"Managers\") together, the \"Indirect Reporting Persons\"). The Mangers are Forest Baskett, Ali Behbahani, Carmen Chang, Anthony Florence, Jr., Mohamad Makhzoumi, Edward Mathers, Scott Sandell, Paul Walker and Rick Yang. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Indirect Reporting Persons have no pecuniary interest."}],"balance_after":242945,"derivative":{"exercise_price":0.001,"underlying":"Common Stock","underlying_shares":242945},"source":{"system":"sec-edgar","filing":"0001193125-26-104719","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1796820/000119312526104719/ownership.xml","form_type":"4"}},{"id":846292,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":61257,"kind":"organization","name":"New Enterprise Associates 17, L.P.","position":1,"cik":"0001768564","reported_name":"New Enterprise Associates 17, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61258,"kind":"organization","name":"NEA Partners 17, L.P.","position":2,"cik":"0001796820","reported_name":"NEA Partners 17, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61259,"kind":"organization","name":"NEA 17 GP, LLC","position":3,"cik":"0001796821","reported_name":"NEA 17 GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-12T20:15:13.000Z","date":"2026-03-10","kind":"purchase","planned":false,"acquired":true,"shares":207100,"price":11.11,"value":2300881.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by New Enterprise Associates 17, L.P. (\"NEA 17\") and are indirectly held by NEA Partners 17, L.P. (\"NEA Partners 17\"), the sole general partner of NEA 17, NEA 17 GP, LLC (\"NEA 17 GP\"), the sole general partner of NEA Partners 17, and the individual managers of NEA 17 GP (NEA Partners 17, NEA 17 GP and the individual managers of NEA 17 GP (collectively, the \"Managers\") together, the \"Indirect Reporting Persons\"). The Mangers are Forest Baskett, Ali Behbahani, Carmen Chang, Anthony Florence, Jr., Mohamad Makhzoumi, Edward Mathers, Scott Sandell, Paul Walker and Rick Yang. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Indirect Reporting Persons have no pecuniary interest."}],"balance_after":1297893,"source":{"system":"sec-edgar","filing":"0001193125-26-104719","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1796820/000119312526104719/ownership.xml","form_type":"4"}},{"id":845752,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":61210,"kind":"person","name":"BASKETT FOREST","position":1,"cik":"0001277631","reported_name":"BASKETT FOREST","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2026-03-12T20:15:09.000Z","date":"2026-03-10","kind":"purchase","planned":false,"acquired":true,"shares":242945,"price":11.109,"value":2698876.005,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":242945,"derivative":{"exercise_price":0.001,"underlying":"Common Stock","underlying_shares":242945},"source":{"system":"sec-edgar","filing":"0001193125-26-104716","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1277631/000119312526104716/ownership.xml","form_type":"4"}},{"id":845751,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":61210,"kind":"person","name":"BASKETT FOREST","position":1,"cik":"0001277631","reported_name":"BASKETT FOREST","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-12T20:15:09.000Z","date":"2026-03-10","kind":"purchase","planned":false,"acquired":true,"shares":207100,"price":11.11,"value":2300881.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":1297893,"source":{"system":"sec-edgar","filing":"0001193125-26-104716","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1277631/000119312526104716/ownership.xml","form_type":"4"}},{"id":845618,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2026-03-12T20:15:04.000Z","date":"2026-03-10","kind":"purchase","planned":false,"acquired":true,"shares":242945,"price":11.109,"value":2698876.005,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":242945,"derivative":{"exercise_price":0.001,"underlying":"Common Stock","underlying_shares":242945},"source":{"system":"sec-edgar","filing":"0001193125-26-104714","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000119312526104714/ownership.xml","form_type":"4"}},{"id":845617,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-12T20:15:04.000Z","date":"2026-03-10","kind":"purchase","planned":false,"acquired":true,"shares":207100,"price":11.11,"value":2300881.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":1297893,"source":{"system":"sec-edgar","filing":"0001193125-26-104714","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000119312526104714/ownership.xml","form_type":"4"}},{"id":920933,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":26137,"kind":"person","name":"Aiyar Ram","position":1,"cik":"0001997920","reported_name":"Aiyar Ram","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-03T21:17:03.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option vest in 48 equal monthly installments commencing from February 2, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":80000,"derivative":{"exercise_price":13.05,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001193125-26-035591","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312526035591/ownership.xml","form_type":"4"}},{"id":920932,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":26137,"kind":"person","name":"Aiyar Ram","position":1,"cik":"0001997920","reported_name":"Aiyar Ram","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-03T21:17:03.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon settlement of a restricted stock unit (RSU) granted under the Issuer's 2023 Stock Option and Incentive Plan (the 2023 Plan) that will vest as follows: 50% on August 3, 2026 and 50% on February 1, 2027, in each case subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001193125-26-035591","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312526035591/ownership.xml","form_type":"4"}},{"id":920931,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":29672,"kind":"person","name":"Vincent Loic A","position":1,"cik":"0002063400","reported_name":"Vincent Loic A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-03T21:14:02.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in 48 equal monthly installments commencing from February 2, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":35000,"derivative":{"exercise_price":13.05,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001193125-26-035564","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312526035564/ownership.xml","form_type":"4"}},{"id":922406,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":29811,"kind":"person","name":"Dolan Oliver","position":1,"cik":"0002053835","reported_name":"Dolan Oliver","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-03T21:11:04.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in 48 equal monthly installments commencing from February 2, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":13.05,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193125-26-035541","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2053835/000119312526035541/ownership.xml","form_type":"4"}},{"id":922344,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":29801,"kind":"person","name":"Cerio Jeffrey","position":1,"cik":"0002033618","reported_name":"Cerio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-03T21:08:03.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in 48 equal monthly installments commencing from February 2, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":23000,"derivative":{"exercise_price":13.05,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001193125-26-035518","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2033618/000119312526035518/ownership.xml","form_type":"4"}},{"id":920930,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":29671,"kind":"person","name":"Chappell Todd","position":1,"cik":"0001997992","reported_name":"Chappell Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-03T21:05:02.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in 48 equal monthly installments commencing from February 2, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":38000,"derivative":{"exercise_price":13.05,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":38000},"source":{"system":"sec-edgar","filing":"0001193125-26-035481","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312526035481/ownership.xml","form_type":"4"}},{"id":967019,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":29671,"kind":"person","name":"Chappell Todd","position":1,"cik":"0001997992","reported_name":"Chappell Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-12-16T21:11:03.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":20132,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares of common stock issuable upon settlement of a restricted stock unit (RSU) granted under the Issuer's 2023 Stock Option and Incentive Plan (the 2023 Plan) that will vest as follows: 50% on June 15, 2026 and 50% on December 15, 2026, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date."}],"balance_after":20132,"source":{"system":"sec-edgar","filing":"0001193125-25-320864","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312525320864/ownership.xml","form_type":"4"}},{"id":967015,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":29672,"kind":"person","name":"Vincent Loic A","position":1,"cik":"0002063400","reported_name":"Vincent Loic A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-12-16T21:09:04.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":21715,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares of common stock issuable upon settlement of a restricted stock unit (RSU) granted under the Issuer's 2023 Stock Option and Incentive Plan (the 2023 Plan) that will vest as follows: 50% on June 15, 2026 and 50% on December 15, 2026, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date."}],"balance_after":21715,"source":{"system":"sec-edgar","filing":"0001193125-25-320859","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312525320859/ownership.xml","form_type":"4"}},{"id":967945,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":29801,"kind":"person","name":"Cerio Jeffrey","position":1,"cik":"0002033618","reported_name":"Cerio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2025-12-16T21:07:03.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":41902,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares of common stock issuable upon settlement of a restricted stock unit (RSU) granted under the Issuer's 2023 Stock Option and Incentive Plan (the 2023 Plan) that will vest as follows: 50% on June 15, 2026 and 50% on December 15, 2026, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date."}],"balance_after":41902,"source":{"system":"sec-edgar","filing":"0001193125-25-320851","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2033618/000119312525320851/ownership.xml","form_type":"4"}},{"id":967957,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":29811,"kind":"person","name":"Dolan Oliver","position":1,"cik":"0002053835","reported_name":"Dolan Oliver","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Common Stock","published_at":"2025-12-16T21:05:07.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":21482,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares of common stock issuable upon settlement of a restricted stock unit (RSU) granted under the Issuer's 2023 Stock Option and Incentive Plan (the 2023 Plan) that will vest as follows: 50% on June 15, 2026 and 50% on December 15, 2026, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date."}],"balance_after":21482,"source":{"system":"sec-edgar","filing":"0001193125-25-320841","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2053835/000119312525320841/ownership.xml","form_type":"4"}},{"id":1112876,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:40:18.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":6010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date."}],"balance_after":6010,"derivative":{"exercise_price":14.87,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":6010},"source":{"system":"sec-edgar","filing":"0000950170-25-085495","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000095017025085495/ownership.xml","form_type":"4"}},{"id":1113782,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":39332,"kind":"person","name":"Meyers Rachel","position":1,"cik":"0002001472","reported_name":"Meyers Rachel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:32:03.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":6010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date."}],"balance_after":6010,"derivative":{"exercise_price":14.87,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":6010},"source":{"system":"sec-edgar","filing":"0000950170-25-085480","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2001472/000095017025085480/ownership.xml","form_type":"4"}},{"id":1113164,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":39214,"kind":"person","name":"Bermingham Nessan","position":1,"cik":"0001377759","reported_name":"Bermingham Nessan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:29:03.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":6010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date."}],"balance_after":6010,"derivative":{"exercise_price":14.87,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":6010},"source":{"system":"sec-edgar","filing":"0000950170-25-085455","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377759/000095017025085455/ownership.xml","form_type":"4"}},{"id":1112832,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":39150,"kind":"person","name":"Knobil Katharine","position":1,"cik":"0001768011","reported_name":"Knobil Katharine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:26:03.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":6010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date."}],"balance_after":6010,"derivative":{"exercise_price":14.87,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":6010},"source":{"system":"sec-edgar","filing":"0000950170-25-085435","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000095017025085435/ownership.xml","form_type":"4"}},{"id":1114027,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":18826,"kind":"person","name":"FORMELA JEAN FRANCOIS","position":1,"cik":"0001030575","reported_name":"FORMELA JEAN FRANCOIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:23:04.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":6010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date."}],"balance_after":6010,"derivative":{"exercise_price":14.87,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":6010},"source":{"system":"sec-edgar","filing":"0000950170-25-085424","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030575/000095017025085424/ownership.xml","form_type":"4"}},{"id":1112932,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":39174,"kind":"person","name":"PEARSON TIMOTHY R","position":1,"cik":"0001528617","reported_name":"PEARSON TIMOTHY R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:20:08.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":6010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date."}],"balance_after":6010,"derivative":{"exercise_price":14.87,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":6010},"source":{"system":"sec-edgar","filing":"0000950170-25-085411","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1528617/000095017025085411/ownership.xml","form_type":"4"}},{"id":1186812,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":29811,"kind":"person","name":"Dolan Oliver","position":1,"cik":"0002053835","reported_name":"Dolan Oliver","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T01:46:19.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in 48 equal monthly installments commencing from March 27, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":15.95,"expiration_date":"2035-03-26","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-25-048848","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2053835/000095017025048848/ownership.xml","form_type":"4"}},{"id":1185899,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":29672,"kind":"person","name":"Vincent Loic A","position":1,"cik":"0002063400","reported_name":"Vincent Loic A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T01:46:16.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest as to 25% of the shares on March 31, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date"}],"balance_after":70000,"derivative":{"exercise_price":15.95,"expiration_date":"2035-03-30","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0000950170-25-048847","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000095017025048847/ownership.xml","form_type":"4"}},{"id":1282316,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":29801,"kind":"person","name":"Cerio Jeffrey","position":1,"cik":"0002033618","reported_name":"Cerio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-05T21:37:37.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":29000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in 48 equal monthly installments commencing from February 3, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":29000,"derivative":{"exercise_price":33.5,"expiration_date":"2035-02-02","underlying":"Common Stock","underlying_shares":29000},"source":{"system":"sec-edgar","filing":"0000950170-25-014574","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2033618/000095017025014574/ownership.xml","form_type":"4"}},{"id":1281386,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":83549,"kind":"person","name":"Agarwal Vineet","position":1,"cik":"0001997973","reported_name":"Agarwal Vineet","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-05T21:29:42.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in 48 equal monthly installments commencing from February 3, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":33.5,"expiration_date":"2035-02-02","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-25-014551","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000095017025014551/ownership.xml","form_type":"4"}},{"id":1281385,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":26137,"kind":"person","name":"Aiyar Ram","position":1,"cik":"0001997920","reported_name":"Aiyar Ram","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-05T21:21:26.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in 48 equal monthly installments commencing from February 3, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":100000,"derivative":{"exercise_price":33.5,"expiration_date":"2035-02-02","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000950170-25-014517","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000095017025014517/ownership.xml","form_type":"4"}},{"id":1281383,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":29671,"kind":"person","name":"Chappell Todd","position":1,"cik":"0001997992","reported_name":"Chappell Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-05T21:21:01.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":34500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in 48 equal monthly installments commencing from February 3, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":34500,"derivative":{"exercise_price":33.5,"expiration_date":"2035-02-02","underlying":"Common Stock","underlying_shares":34500},"source":{"system":"sec-edgar","filing":"0000950170-25-014515","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000095017025014515/ownership.xml","form_type":"4"}},{"id":1282290,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":83564,"kind":"person","name":"Olugemo Olukemi","position":1,"cik":"0002022212","reported_name":"Olugemo Olukemi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-05T16:14:52.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in 48 equal monthly installments commencing from February 3, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":42000,"derivative":{"exercise_price":33.5,"expiration_date":"2035-02-02","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0000950170-25-014478","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022212/000095017025014478/ownership.xml","form_type":"4"}},{"id":1368110,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":83549,"kind":"person","name":"Agarwal Vineet","position":1,"cik":"0001997973","reported_name":"Agarwal Vineet","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-13T00:40:46.000Z","date":"2024-11-11","kind":"exercise","planned":true,"acquired":false,"shares":800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 19, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option vest as to 25% of the shares on May 11, 2022, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":30807,"derivative":{"exercise_price":11.68,"expiration_date":"2031-05-29","underlying":"Common Stock","underlying_shares":800},"source":{"system":"sec-edgar","filing":"0000950170-24-125822","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000095017024125822/ownership.xml","form_type":"4"}},{"id":1368109,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":83549,"kind":"person","name":"Agarwal Vineet","position":1,"cik":"0001997973","reported_name":"Agarwal Vineet","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-11-13T00:40:46.000Z","date":"2024-11-11","kind":"sale","planned":true,"acquired":false,"shares":800,"price":70,"value":56000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 19, 2024."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-125822","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000095017024125822/ownership.xml","form_type":"4"}},{"id":1368108,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":83549,"kind":"person","name":"Agarwal Vineet","position":1,"cik":"0001997973","reported_name":"Agarwal Vineet","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-11-13T00:40:46.000Z","date":"2024-11-11","kind":"exercise","planned":true,"acquired":true,"shares":800,"price":11.68,"value":9344.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 19, 2024."}],"balance_after":800,"source":{"system":"sec-edgar","filing":"0000950170-24-125822","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000095017024125822/ownership.xml","form_type":"4"}},{"id":1383946,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":83549,"kind":"person","name":"Agarwal Vineet","position":1,"cik":"0001997973","reported_name":"Agarwal Vineet","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-18T23:43:18.000Z","date":"2024-10-17","kind":"exercise","planned":true,"acquired":false,"shares":953,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 19, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The shares subject to the option vest in 48 equal monthly installments commencing from November 3, 2023, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":45594,"derivative":{"exercise_price":14.98,"expiration_date":"2033-11-02","underlying":"Common Stock","underlying_shares":953},"source":{"system":"sec-edgar","filing":"0000950170-24-115723","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000095017024115723/ownership.xml","form_type":"4"}},{"id":1383945,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":83549,"kind":"person","name":"Agarwal Vineet","position":1,"cik":"0001997973","reported_name":"Agarwal Vineet","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-18T23:43:18.000Z","date":"2024-10-17","kind":"exercise","planned":true,"acquired":false,"shares":9263,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 19, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The shares subject to the option vest as to 25% of the shares on May 11, 2022, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":31607,"derivative":{"exercise_price":11.68,"expiration_date":"2031-05-29","underlying":"Common Stock","underlying_shares":9263},"source":{"system":"sec-edgar","filing":"0000950170-24-115723","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000095017024115723/ownership.xml","form_type":"4"}},{"id":1383944,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":83549,"kind":"person","name":"Agarwal Vineet","position":1,"cik":"0001997973","reported_name":"Agarwal Vineet","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-10-18T23:43:18.000Z","date":"2024-10-17","kind":"sale","planned":true,"acquired":false,"shares":25,"price":82.89,"value":2072.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 19, 2024."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-115723","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000095017024115723/ownership.xml","form_type":"4"}},{"id":1383943,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":83549,"kind":"person","name":"Agarwal Vineet","position":1,"cik":"0001997973","reported_name":"Agarwal Vineet","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-10-18T23:43:18.000Z","date":"2024-10-17","kind":"sale","planned":true,"acquired":false,"shares":317,"price":81.48,"value":25829.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 19, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.20 to $82.00, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Issuer, any security holder of the Issuer, or the SEC staff upon request."}],"balance_after":25,"source":{"system":"sec-edgar","filing":"0000950170-24-115723","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000095017024115723/ownership.xml","form_type":"4"}},{"id":1383942,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":83549,"kind":"person","name":"Agarwal Vineet","position":1,"cik":"0001997973","reported_name":"Agarwal Vineet","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-10-18T23:43:18.000Z","date":"2024-10-17","kind":"sale","planned":true,"acquired":false,"shares":4961,"price":80.5027,"value":399373.8947,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 19, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $80.15 to $81.14, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Issuer, any security holder of the Issuer, or the SEC staff upon request."}],"balance_after":342,"source":{"system":"sec-edgar","filing":"0000950170-24-115723","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000095017024115723/ownership.xml","form_type":"4"}},{"id":1383941,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":83549,"kind":"person","name":"Agarwal Vineet","position":1,"cik":"0001997973","reported_name":"Agarwal Vineet","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-10-18T23:43:18.000Z","date":"2024-10-17","kind":"sale","planned":true,"acquired":false,"shares":1815,"price":79.7911,"value":144820.8465,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 19, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $79.12 to $80.115, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Issuer, any security holder of the Issuer, or the SEC staff upon request."}],"balance_after":5303,"source":{"system":"sec-edgar","filing":"0000950170-24-115723","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000095017024115723/ownership.xml","form_type":"4"}},{"id":1383940,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":83549,"kind":"person","name":"Agarwal Vineet","position":1,"cik":"0001997973","reported_name":"Agarwal Vineet","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-10-18T23:43:18.000Z","date":"2024-10-17","kind":"sale","planned":true,"acquired":false,"shares":457,"price":78.5857,"value":35913.6649,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 19, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $78.07 to $78.935, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Issuer, any security holder of the Issuer, or the SEC staff upon request."}],"balance_after":7118,"source":{"system":"sec-edgar","filing":"0000950170-24-115723","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000095017024115723/ownership.xml","form_type":"4"}}],"next_cursor":"2024-10-18T23:43:18.000000Z,1383940"}